The objective is to evaluate the efficacy and safety of each C1 esterase inhibitor plus standard care and use of icatibant plus standard care vs. standard care alone in hospitalized adult patients with pneumonia caused by COVID-19. The gene discussed is C1S; the disease is susceptibility to pneumonia measurement.